依瑞奈尤单抗 (Aimovig)

概览

Erenumab is a calcitonin-gene related peptide antagonist used to prevent migraines.

作用机制

Erenumab is a human monoclonal antibody that has been designed to bind specifically to the calcitonin gene-related peptide (CGRP) receptor and antagonize the CGRP receptor function . Studies since 1985 have demonstrated that CGRP levels increase during acute migraine attacks in migraine-suffering patients but normalize after efficacious sumatriptan therapy . Moreover, research has also shown that intravenous administration of CGRP can induce migraine-like attacks in migraine-suffering patients . For all these reasons, the binding and antagonism of CGRP receptors was designed to be mechanism of action for erenumab to take advantage of in reversing the migraine-inducing activity of natural CGRP. CGRP and its receptor are expressed in both the peripheral and the central nervous system . In addition to playing a role in cranial nociception, CGRP is also a potent general arterial vasodilator . At peripheral synapses, CGRP released from trigeminal terminals results in vasodilation via CGRP receptors on the smooth muscle cells of meningeal and cerebral blood vessels .

适应症

Erenumab is indicated for the preventative treatment of migraine in adults .

• Migraine